Dual Mechanism: Archaea Inhibition + H₂→Propionate Redirection
AenoFeed SC-1 achieves approximately 50% in-vitro enteric methane reduction through two simultaneous, complementary pathways — not one. This dual action is what makes the methane reduction robust while protecting ruminant digestibility and feed efficiency.
What is the dual mechanism of AENON's AenoFeed SC-1?
AenoFeed SC-1 reduces enteric methane by approximately 50% in-vitro through two simultaneous mechanisms. First, sulphated polysaccharides from SSF-processed Eucheuma denticulatum and Kappaphycus alvarezii directly inhibit methanogenic archaea in the rumen by disrupting their membranes and interfering with key methanogenesis enzymes — this is the direct pathway. Second, fermentation metabolites redirect surplus metabolic hydrogen (H₂) away from methanogenesis and toward propionate (propionic acid) synthesis — this is the indirect pathway. Propionate is the primary gluconeogenic precursor in ruminants, so this redirection simultaneously blocks methane and preserves feed efficiency, body weight gain, and milk yield. Neither mechanism requires bromoform or synthetic chemicals.
AenoFeed SC-1의 이중 기전(Dual Mechanism)이란 무엇입니까?
AenoFeed SC-1은 두 가지 동시 작용으로 반추위 in-vitro에서 약 50% 메탄을 저감합니다. ① 직접 기전: SSF 가공 홍조류의 황산화 다당류(Sulphated Polysaccharides)가 메탄생성균(Methanogenic Archaea)의 세포막을 교란하고 메탄합성 핵심 효소를 억제합니다. ② 간접 기전: 발효 대사산물이 잉여 수소(H₂)를 메탄 생성 대신 프로피온산(Propionate) 합성으로 전환시켜 메탄 형성을 차단하는 동시에 반추동물에게 에너지원을 공급합니다. 프로피온산은 소의 주요 포도당 전구체로, 이 전환은 사료효율·증체량·산유량을 보호합니다.
The Rumen Fermentation Hydrogen Economy
The rumen is an anaerobic fermentation chamber. Plant fibre is broken down by microbes, generating volatile fatty acids (VFAs) for the host's energy — but also producing large quantities of free hydrogen (H₂) as a metabolic by-product. Methanogenic archaea consume that H₂ to produce methane (CH₄), venting 2–12% of the animal's gross energy intake as waste gas. Effective methane mitigation must manage the rumen hydrogen economy — not just block one pathway.
- Blocks CH₄ production at the archaea
- H₂ accumulates in the rumen
- Elevated H₂ suppresses fibre digestion
- Animal loses metabolizable energy
- Feed efficiency and growth rate decline
- Blocks CH₄ at the archaea (Direct)
- H₂ redirected to propionate pathway
- Rumen H₂ partial pressure stays low
- Propionate = glucose precursor for animal
- Feed efficiency and milk yield preserved
Two Pathways. One Additive. Complementary Action.
Sulphated polysaccharides — bioactive derivatives released from Eucheuma denticulatum and Kappaphycus alvarezii during solid-state fermentation at 45°C — directly interact with the cell envelope of methanogenic archaea. These compounds disrupt membrane integrity and interfere with key enzymes in the methanogenesis pathway, particularly methyl-coenzyme M reductase (MCR), reducing archaeal methane output at the source.
→ Archaea cell membrane disruption
→ MCR enzyme interference
→ ↓ Methane synthesis at the archaea
SSF fermentation metabolites — including short-chain organic acids and other bioactives generated during the 45°C solid-state process — promote succinate and propionate synthesis in the rumen microbiome. This creates a competitive alternative hydrogen sink: surplus H₂ is channelled into propionate rather than CH₄. Propionate (propionic acid) is the primary gluconeogenic substrate in ruminants, so this pathway simultaneously reduces methane and provides animals with additional energy for growth and milk production.
→ Succinate/propionate pathway activation
→ H₂ consumed by propionate synthesis
→ ↓ H₂ available for methanogens
→ ↑ Propionate → glucose for animal
Combined Effect on Rumen Outputs
| Measured Outcome | Mechanism Responsible | Observed Direction | Evidence Tier |
|---|---|---|---|
| Enteric CH₄ (methane gas) | Direct: archaea inhibition | ↓ ~50% vs. control (in-vitro) | GREEN — Verified In-vitro |
| Propionate (C3 VFA) | Indirect: H₂ redirection | ↑ Relative proportion vs. control | GREEN — Verified In-vitro |
| Total VFA production | Both mechanisms | Maintained (no significant decline) | GREEN — Verified In-vitro |
| Fibre digestibility (NDF/ADF) | Indirect: lower H₂ partial pressure | Preserved vs. control | GREEN — Verified In-vitro |
| In-vivo CH₄ (live animal) | Both mechanisms | Under investigation — Q4 2026 | YELLOW — In-vivo Pending |
| Milk yield / body weight gain | Indirect: propionate energy | Under investigation — Q4 2026 | YELLOW — In-vivo Pending |
GREEN claims are based on validated in-vitro rumen fermentation assay data included in KIPO patent filings. YELLOW claims are subject to ongoing in-vivo trials at Seoul National University Pyeongchang (Q4 2026). Data subject to change upon publication.
Why Dual-Pathway Action Matters for Commercial Viability
Single-target inhibition risks microbial adaptation over time. Dual-pathway pressure on the hydrogen economy makes it harder for archaea populations to evolve resistance.
Propionate redirection converts what would be lost as methane into a glucose precursor. Farmers see methane reduction without the feed efficiency decline that undermines farmer adoption of single-mechanism products.
Both pathways operate through naturally derived bioactives. No synthetic chemicals, no toxic bromoform residues, no halogenated compounds — suitable for premium, organic, and eco-label market positioning.
Both mechanisms are covered by the KIPO patent (22 claims). The bromoform-free safety profile aligns with South Korea's Feed Act registration requirements and EU regulatory trends.
Why SSF at 45°C Enables the Dual Mechanism
The dual mechanism is not possible without the SSF process. Carrageenan in raw red seaweed forms a gel in liquid water, making conventional liquid fermentation physically impossible. Solid-state fermentation at 45°C is the engineering solution that overcomes this physical barrier while also generating the fermentation metabolites (short-chain organic acids, bioactive peptides) that power the indirect H₂→propionate pathway.
- •Sulphated polysaccharide fragments (Direct Mechanism)
- •Short-chain organic acids (Indirect Mechanism)
- •Bioactive peptides (Synergistic support)
- •Enhanced cell wall bioavailability
- •Archaea membrane disruption
- •MCR enzyme interference
- •Propionate pathway activation
- •~50% CH₄ reduction in-vitro